Retro Biosciences, backed by Sam Altman, is leveraging OpenAI's GPT-4b micro model in research aimed at extending human lifespan by 10 years. The AI assists in reengineering proteins known as Yamanaka factors, which can convert skin cells into stem cells. Initial results suggest the AI's suggestions have significantly improved protein effectiveness. While commercial applications may take years, the project highlights AI's potential in advancing longevity research, despite ethical concerns regarding Altman's dual investment roles.